-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma pivots to precision oncology, prioritizing CD228V melanoma proof-of-concept study

PUBT·09/08/2026 11:31:08
Listen to the news
Medicus Pharma pivots to precision oncology, prioritizing CD228V melanoma proof-of-concept study
  • Medicus shifted strategy to become a precision oncology-led biotech, prioritizing CD228V as its main development and capital focus.
  • Initial goal is clinical proof-of-concept for CD228V in relapsed or refractory melanoma, supported by a biomarker-led translational plan.
  • SkinJect development will concentrate on Gorlin syndrome, targeting an NDA-enabling Phase 2b registrational study authorized by the FDA.
  • Teverelix will focus on a roughly 126-patient Phase 2 acute urinary retention program, alongside the PRECISION-E2 Phase 2a endometriosis study.
  • Other programs will be advanced through capital-efficient partnerships to preserve cash while pursuing additional clinical opportunities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080730PRIMZONEFULLFEED9822565) on September 08, 2026, and is solely responsible for the information contained therein.